Who receives outpatient monitoring during high-risk depression treatment periods?
OBJECTIVE
To examine the intensity of monitoring received by important patient subgroups during high-risk periods (the 12 weeks after psychiatric hospitalization and after new antidepressant starts).


METHODS
Retrospective secondary analysis of data from the Veterans Affairs (VA) National Registry for Depression using patients aged 65 and older receiving depression treatment from 1999 to 2004.


METHODS
VA healthcare system.


METHODS
VA patients in depression treatment between April 1, 1999, and September 30, 2004, who had psychiatric inpatient stays (n=73,137) or new antidepressant starts (n=421,536).


METHODS
The relationship between the number of outpatient visits for each group and patient characteristics in the 12-week period after psychiatric hospitalizations and antidepressant starts.


RESULTS
The characteristic associated with significantly lower rates of monitoring for both high-risk treatment periods was aged 65 and older. White race and living in the south or northeast were also associated with significantly lower rates of monitoring after new antidepressant starts and inpatient stays, respectively. Substance abuse disorders were associated with greater monitoring after both types of depression events but did not seem to interact with other patient characteristics in determining levels of monitoring.


CONCLUSIONS
VA patients who are older, white, and living in the south or northeast receive less-intensive monitoring during high-risk treatment periods for suicide. This is of concern, given that older patients appear to be at higher risk for suicide, particularly after inpatient stays, and may need particular attention during this time frame. Adapted interventions and proactive outreach may be needed that target this patient group.
Kales
Helen C
HC
Serious Mental Illness Treatment, Research, and Evaluation Center, Ann Arbor Center of Excellence, Department of Veterans Affairs, Ann Arbor, Michigan, USA. kales@umich.edu
Kim
H Myra
HM
Austin
Karen L
KL
Valenstein
Marcia
M
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006787:Hospitals, Veterans; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012111:Residence Characteristics; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D019966:Substance-Related Disorders / Q000150:complications; D044465:White People; D000092864:Suicide Prevention
D000928:Antidepressive Agents
Am J Manag Care. 2006 Aug;12(8):453-61
16886888
Biol Psychiatry. 2002 Aug 1;52(3):293-303
12182934
J Affect Disord. 2009 Jan;112(1-3):50-8
18945495
Am J Psychiatry. 2006 Jul;163(7):1219-25
16816227
Med Care. 2008 Aug;46(8):813-20
18665061
Psychiatr Serv. 2004 Dec;55(12):1386-91
15572566
Psychiatr Clin North Am. 2005 Dec;28(4):763-84, vii
16325728
Lancet. 2005 Jun 4-10;365(9475):1961-70
15936426
Am J Geriatr Psychiatry. 2000 Fall;8(4):301-9
11069270
J Gen Intern Med. 2000 Aug;15(8):527-34
10940143
Arch Fam Med. 1994 Oct;3(10):908-17
8000563
J Geriatr Psychiatry Neurol. 2002 Fall;15(3):147-55
12230085
Psychiatr Serv. 2002 Dec;53(12):1599-604
12461222
Arch Gen Psychiatry. 2000 Jun;57(6):601-7
10839339
Am J Psychiatry. 2008 Jan;165(1):42-50
17986680
Psychiatr Serv. 2000 Jun;51(6):795-800
10828113
Arch Fam Med. 1999 May-Jun;8(3):249-56
10333821
J Chronic Dis. 1987;40(5):373-83
3558716
Adm Policy Ment Health. 2008 Nov;35(6):468-76
18712470
Med Care. 2003 May;41(5):669-80
12719691
Milbank Q. 1999;77(2):225-56, 174
10392163
Psychiatr Serv. 2004 Dec;55(12):1379-85
15572565
J Affect Disord. 2004 Mar;78(3):209-17
15013245